News | February 23, 2022
ACUITE upgrades ratings of Bal Pharma
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
He will continue to lead business in LATAM and Asia regions in this new role
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
The facility will manufacture its Herceptin biosimilar, Tuznue
Subscribe To Our Newsletter & Stay Updated
